Ofatumumab (Arzerra) for Chronic Lymphatic Leukaemia

The orphan drug ofatumumab demonstrated a high objective response in patients who are refractory for fludarabine and alemtuzumab. Based on a retrospective comparison, and in view of the severity of the disease and the absence of an alternative treatment, the conclusion is that, in spite of the limited data, ofatumumab has a therapeutic added value in comparison with not using ofatumumab for the treatment of chronic lymphatic leukaemia (CLL) in patients who are refractory for fludarabine and alemtuzumab.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.